ClinVar Miner

Submissions for variant NM_000492.3(CFTR):c.1040G>A (p.Arg347His) (rs77932196)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000508504 SCV000603045 pathogenic not specified 2017-02-03 criteria provided, single submitter clinical testing
CFTR2 RCV000007602 SCV000071520 pathogenic Cystic fibrosis 2017-03-17 reviewed by expert panel research
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000224726 SCV000281142 pathogenic not provided 2015-04-06 criteria provided, single submitter clinical testing
Counsyl RCV000007602 SCV000485223 pathogenic Cystic fibrosis 2015-11-24 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000007602 SCV000052118 pathogenic Cystic fibrosis 2015-04-06 no assertion criteria provided clinical testing
Invitae RCV000007602 SCV000074220 pathogenic Cystic fibrosis 2016-04-01 criteria provided, single submitter clinical testing This sequence change replaces arginine with histidine at codon 347 of the CFTR protein (p.Arg347His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine. This variant is present in population databases (rs77932196, ExAC 0.001%). This variant is clearly defined as a Cystic Fibrosis (CF) causative allele (PMID: 23974870) and is included in the American College of Medical Genetics (ACMG) panel of CF variants (PMID: 15371902). ClinVar contains an entry for this variant (Variation ID: 7182). For these reasons, this variant has been classified as Pathogenic.
Mendelics RCV000007602 SCV000886207 pathogenic Cystic fibrosis 2018-11-05 criteria provided, single submitter clinical testing
OMIM RCV000007602 SCV000027803 pathogenic Cystic fibrosis 2018-04-09 no assertion criteria provided literature only
PharmGKB RCV000660858 SCV000783097 drug response ivacaftor response - Efficacy 2018-03-27 reviewed by expert panel curation PharmGKB Level of Evidence 1A: Annotation for a variant-drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.